Larry D. Smith
Architects at 107 St, Omaha, NE
License number
South Dakota 4843
Expiration Date
Dec 31, 2018
Category
Architect
Address
Address
3337 N 107Th St, Omaha, NE 68134
Phone
(402) 493-9611
Professional information
See more information about Larry D. Smith at trustoria.com
Counselor At 24Hr Fitness
Counselor At 24Hr Fitness
Position:
counselor at 24HR Fitness
Location:
Greater Omaha Area
Industry:
Health, Wellness and Fitness
Work:
24HR Fitness
-
counselor
Vice President At Avant Architects, Inc.
Vice President At Avant Architects, Inc.
Position:
Vice President at Avant Architects, Inc.
Location:
Greater Omaha Area
Industry:
Architecture & Planning
Work:
Avant Architects, Inc.
-
Vice President
Methods For Identifying Inducers And Inhibitors Of Proteolytic Antibodies, Compositions And Their Uses
Methods For Identifying Inducers And Inhibitors Of Proteolytic Antibodies, Compositions And Their Uses
US Patent:
6235714, May 22, 2001
Filed:
Mar 23, 1998
Appl. No.:
9/046373
Inventors:
Sudhir Paul - Houston TX
Gennady Gololobov - Houston TX
Larry J. Smith - Omaha NE
Gennady Gololobov - Houston TX
Larry J. Smith - Omaha NE
International Classification:
A61K 3800
US Classification:
514 12
Abstract:
Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders.
Therapeutic Oligonucleotides Targeting The Human Mdr1 And Mrp Genes
Therapeutic Oligonucleotides Targeting The Human Mdr1 And Mrp Genes
US Patent:
5683987, Nov 4, 1997
Filed:
Jun 7, 1995
Appl. No.:
8/487141
Inventors:
Larry J. Smith - Omaha NE
Assignee:
The Board of Regents of the University of Nebraska - Lincoln NE
International Classification:
A01N 4304, C07H 2102, C07H 7104, C07H 1904
US Classification:
514 44
Abstract:
The present invention provides novel compositions and methods useful in cancer therapy for inhibiting the multidrug resistance phenotype, which often thwarts long-term chemotherapeutic regimens. The novel compositions of matter comprise oligonucleotides targeted to the human MDR1 and MRP genes, which inhibit expression of these genes, thereby rendering tumors and other forms of cancer more susceptible to the cytotoxic effects of chemotherapeutic agents. Oligonucleotides are also provided that inhibit the multidrug resistance phenotype by exerting an aptameric effect.
Methods And Compositions For The Treatment Of Medical Conditions Involving Cellular Reprogramming
Methods And Compositions For The Treatment Of Medical Conditions Involving Cellular Reprogramming
US Patent:
2012015, Jun 21, 2012
Filed:
Apr 14, 2009
Appl. No.:
13/264482
Inventors:
Larry J. Smith - Omaha NE, US
International Classification:
A61K 49/00, A61K 9/127, A61K 38/00, A61K 38/08, A61K 38/10, A61K 38/16, C12N 5/02, A61P 35/00, A61P 31/14, A61P 25/28, A61P 9/10, A61P 37/02, A61P 3/10, A61P 9/00, A61P 27/02, A61P 25/00, A61P 25/16, A61P 17/06, A61P 11/06, A61P 19/02, A61P 31/12, A61P 7/06, A61P 31/18, A61P 35/02, A61K 31/7088, B82Y 5/00
US Classification:
424 92, 514 44 A, 424450, 514 12, 435375, 977773, 977906
Abstract:
The present invention provides a variety of nucleic acid based therapeutics and methods of use thereof which are effective to beneficially reprogram diseased cells such that they exhibit more desirable phenotypes. Also provided are compositions and methods to reprogram normal cells for medical and commercial purposes.
Therapeutic Oligonucleotides Targeting The Human Mdr1 And Mrp Genes
Therapeutic Oligonucleotides Targeting The Human Mdr1 And Mrp Genes
US Patent:
5874567, Feb 23, 1999
Filed:
Sep 8, 1997
Appl. No.:
8/927561
Inventors:
Larry J. Smith - Omaha NE
Assignee:
The Board of Regents of the University of Nebraska - Lincoln NE
International Classification:
C07H 2104, C12Q 168, C12N 1585
US Classification:
536 245
Abstract:
The present invention provides novel compositions and methods useful in cancer therapy for inhibiting the multidrug resistance phenotype, which often thwarts long-term chemotherapeutic regimens. The novel compositions of matter comprise oligonucleotides targeted to the human MDR1 and MRP genes, which inhibit expression of these genes, thereby rendering tumors and other forms of cancer more susceptible to the cytotoxic effects of chemotherapeutic agents. Oligonucleotides are also provided that inhibit the multidrug resistance phenotype by exerting an aptameric effect.
Methods For Identifying Inducers And Inhibitors Of Proteolytic Antibodies, Compositions And Their Uses
Methods For Identifying Inducers And Inhibitors Of Proteolytic Antibodies, Compositions And Their Uses
US Patent:
6855528, Feb 15, 2005
Filed:
May 22, 2001
Appl. No.:
09/862849
Inventors:
Sudhir Paul - Houston TX, US
Gennady Gololobov - Houston TX, US
Larry J. Smith - Omaha NE, US
Gennady Gololobov - Houston TX, US
Larry J. Smith - Omaha NE, US
Assignee:
University of Nebraska Board of Regents - Lincoln NE
International Classification:
C12N009/00, A61K038/04, A61K038/43
US Classification:
4351885, 424 941, 514 13
Abstract:
Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens assocated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders.
Method And Compositions For Cellular Reprogramming
Method And Compositions For Cellular Reprogramming
US Patent:
7517644, Apr 14, 2009
Filed:
Jun 7, 1995
Appl. No.:
08/472801
Inventors:
Larry J. Smith - Omaha NE, US
International Classification:
C07H 21/02, A61K 31/70, C12Q 1/68
US Classification:
435 6, 435375, 435377, 514 44, 536 231, 536 241, 536 245
Abstract:
The present invention provides methods and compositions useful in treating certain diseases herein termed “Aberrant Programming Diseases,” including cancer and AIDS. According to one aspect of the invention, there is provided a method for treating an individual having an Aberrant Programming disease comprising administering to said individual an effective amount of a composition selected from the group consisting of an expression vector, a double stranded oligodeoxynucleotide, and an antisense oligodeoxynucleotide; said composition capable of regulating expression of a transcriptional regulator, said transcriptional regulator being expressed by the Aberrant Programming cells and further characterized by exhibiting a therapeutically useful change in said cell behavior in the Reprogramming Test. In a separate embodiment new antisense oligodeoxynucleotides are provided.
Methods And Compositions For Cellular Reprogramming
Methods And Compositions For Cellular Reprogramming
US Patent:
2010001, Jan 14, 2010
Filed:
May 21, 2008
Appl. No.:
12/124943
Inventors:
Larry J. Smith - Omaha NE, US
International Classification:
A61K 31/7088, C12N 5/06
US Classification:
514 44 A, 435375
Abstract:
Compositions and methods useful for the treatment of aberrant programming diseases, particularly those associated with aberrant apoptosis are disclosed
Methods And Compositions For Cellular Reprogramming
Methods And Compositions For Cellular Reprogramming
US Patent:
2010017, Jul 8, 2010
Filed:
Feb 1, 2010
Appl. No.:
12/658042
Inventors:
Larry J. Smith - Omaha NE, US
International Classification:
A61K 9/127, A61K 31/713, A61K 38/19, A61K 48/00, A61P 31/18, A61P 31/16, A61P 31/22, A61P 25/28, A61P 19/02, A61P 37/00, A61P 9/10, C12N 5/10, C12N 5/078, C12N 5/071, C12N 5/074, C12N 5/077
US Classification:
424450, 514 44 A, 514 12, 424 9321, 435375, 435377, 435371, 435372, 435366
Abstract:
Compositions and methods useful for the treatment of aberrant programming diseases, particularly those associated with aberrant apoptosis are disclosed